Cytel Corporation Recruits McKesson Executive, David L. Mahoney, To Board Of Directors.SAN DIEGO--(BUSINESS WIRE)--Sept. 24, 1996--Cytel Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYTL) today announced the election of David L. Mahoney, President, Pharmaceutical and Retail Services, McKesson Corporation, to its Board of Directors. Mr. Mahoney, 42, has overall responsibility for McKesson Corporation's product procurement, retail marketing programs and strategic relationships with pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . In addition to managing the branded and generic pharmaceutical promotional programs for McKesson Drug Company, he oversees McKesson BioServices and Healthcare Delivery System (HDS (Hitachi Data Systems, Santa Clara, CA, www.hds.com) A leading provider of high-end storage hardware, software and services. Part of the Information Systems & Telecommunications Division of Hitachi Ltd. ). Mr. Mahoney served as President of HDS until December 1995. Prior to HDS, Mr. Mahoney served four years as Vice President of strategic planning at McKesson, where he was responsible for planning and corporate development. Prior to joining McKesson, he was a principal with McKinsey & Company in San Francisco. Mr. Mahoney is a member of the Board of Directors of Amor All Corporation. He is a graduate of Princeton University and Harvard Business School Harvard Business School, officially named the Harvard Business School: George F. Baker Foundation, and also known as HBS, is one of the graduate schools of Harvard University. . "We are extremely pleased to add an executive to our Board of Directors with such impressive credentials, and who is on the forefront of the new pharmaceutical marketing environment," said Virgil Thompson, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cytel. Cytel Corporation is a leader in the discovery, design and development of immunotherapeutics, a class of drugs which the company believes will be more selective and have fewer side effects Side effects Effects of a proposed project on other parts of the firm. than drugs currently on the market. Cytel's core technology platforms consist of the Immune Stimulation program under which the Company is developing therapeutic vaccines for infectious diseases and cancers, the Immune Suppression Program which is based on anti-inflammatory cell adhesion inhibitors, and Glycotechnology -- its proprietary enzymatic synthesis technology enabling the manufacture of large quantities of complex carbohydrates complex carbohydrates, n.pl polysaccharides; nutritional compounds composed of multiple monosaccharide (simple sugar) building blocks. Complex carbohydrates include starches, glycogen, and cellulose. at commercially viable prices. CONTACT: Cytel Corporation Karin Eastham Vice President and Chief Financial Officer 619/552-3000 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion